Objectives: Pulmonary vascular dysfunction is associated with adverse prognosis in patients with the acute respiratory distress syndrome; however, the prognostic impact of pulmonary arterial compliance in acute respiratory distress syndrome is not established. Design, Setting, Patients: We performed a retrospective analysis of 363 subjects with acute respiratory distress syndrome who had complete baseline right heart catheterization data from the Fluid and Catheter Treatment Trial to test whether pulmonary arterial compliance at baseline and over the course of treatment predicted mortality. Main Results: Baseline pulmonary arterial compliance (hazard ratio, 1.18 per interquartile range of 1/pulmonary arterial compliance; 95% CI, 1.02-1.37; p = 0.03) and pulmonary vascular resistance (hazard ratio, 1.28 per interquartile range; 95% CI, 1.07-1.53; p = 0.006) both modestly predicted 60-day mortality. Baseline pulmonary arterial compliance remained predictive of mortality when pulmonary vascular resistance was in the normal range (p = 0.02). Between day 0 and day 3, pulmonary arterial compliance increased in acute respiratory distress syndrome survivors and remained unchanged in nonsurvivors, whereas pulmonary vascular resistance did not change in either group. The resistance-compliance product (resistancecompliance time) increased in survivors compared with nonsurvivors, suggesting improvements in right ventricular load. Conclusions: Baseline measures of pulmonary arterial compliance and pulmonary vascular resistance predict mortality in acute respiratory distress syndrome, and pulmonary arterial compliance remains predictive even when pulmonary vascular resistance is normal. Pulmonary arterial compliance and right ventricular load improve over time in acute respiratory distress syndrome survivors. Future studies should assess the impact of right ventricular protective acute respiratory distress syndrome treatment on right ventricular afterload and outcome. (Crit Care Med 2017; 45:422-429) 
Dr. Metkus received funding from the National Heart, Lung, and Blood Institute (T32 salary support), unrestricted research funds from Abbott Diagnostics to support an investigator-initiated study, and received consulting fees from BestDoctors, Inc and Oakstone-EBIX CME unrelated to the current work and is eligible for publishing royalties from McGraw-Hill publishing, unrelated to the current work. He received support for this article research from the National Institutes of Health (NIH). Dr. Mathai served as a consultant for Actelion, Bayer, and Gilead Sciences. Dr. Maron received funding from and serves on the Scientific Advisory Board of Gilead Sciences Inc. He received support for this article research from the NIH, the American Heart Association, and the Cardiovascular Medical Research and Education Foundation. Dr. Hassoun received funding from Gilead (part of the Scientific Advisory Board, unrelated to the current work). Dr. Tedford received support for this article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. he acute respiratory distress syndrome (ARDS) is associated with substantial morbidity and mortality (1) (2) (3) , and refined risk stratification of ARDS patients is needed. ARDS-associated right heart failure has been associated with poor outcome in some (4, 5) but not all (6) studies. Markers of static right ventricular (RV) afterload such as pulmonary vascular resistance (PVR) may predict adverse outcome (7) but do not account for the pulsatile nature of blood flow and wave reflections that contribute to RV afterload. Pulmonary arterial compliance (C PA ) is a major component of RV pulsatile load, which is related both to PVR and left heart filling pressures (8, 9) and may also better characterize RV load when PVR is in the normal range (8, 10) . Lower C PA has been associated with mortality in both pulmonary arterial hypertension and left heart failure (9-12) but has not been studied in ARDS. Given a possible important role of fluid balance and cardiac filling pressure in mitigating outcome in ARDS (13-16), we hypothesized that C PA would predict mortality in patients with ARDS. We also sought to characterize the relationship of C PA and PVR in ARDS and to determine clinical factors associated with both C PA and PVR.
METHODS

Patient Population
The Fluid and Catheter Treatment Trial (FACTT) was conducted by the ARDS Network. The trial randomized 1,000 subjects with ARDS in a 2 × 2 factorial design to placement of either central venous catheter or pulmonary artery catheter and to either a conservative or liberal fluid management strategy (15, 17) . Patients were receiving low tidal volume mechanical ventilation and had a Pao 2 /Fio 2 ratio less than 300 and bilateral infiltrates not referable to hydrostatic edema, which was assessed clinically (15, 17) . Patients with myocardial infarction within the prior 30 days and severe chronic lung disease were excluded from trial enrollment.
We obtained the trial dataset via the National Institutes of Health Biologic Specimen and Data Repository Information Coordinating Center data repository (18) . Five hundred thirteen patients were randomized to pulmonary artery catheter placement. Of these, 146 subjects were excluded because of the lack of complete hemodynamic or clinical data (baseline systolic pulmonary artery pressure, diastolic pulmonary artery pressure, pulmonary artery occlusion pressure [PAOP] , cardiac index, heart rate, height, and weight were required). In addition, four subjects were excluded because recorded hemodynamics generated a negative value for PVR. Therefore, 363 subjects with complete day 0 right heart catheterization data were included in this study. Cardiac filling pressures were measured with subjects supine at end expiration based on ventilator pressure waveforms by study investigators (17) . Cardiac output (CO) was measured by thermodilution (17) . The study was approved by institutional review boards (IRBs) at participating centers. The Johns Hopkins IRB approved this analysis for exempt status given that all datasets were anonymized at the time of receipt.
Markers of Pulmonary Vascular Function
PVR was calculated with the standard formula: (mean pulmonary artery [PA] pressure -PAOP)/CO. C PA was calculated as stroke volume (SV) divided by PA pulse pressure (8) . The resistance-compliance (RC) time is the product of C PA and PVR. In survival analyses, compliance was represented as the inverse of compliance (1/C PA ), so that the effect was directionally comparable with that of PVR.
Statistics
Baseline characteristics and hemodynamics were compared using chi-square test, Student t test, or Wilcoxon rank-sum test as appropriate. Nonlinear regression was performed to identify the best-fit hyperbolic curve for C PA as a function of PVR (the RC curve). Separate RC curves were constructed for those subjects with PAOP less than 12 mm Hg (lowest quartile of PAOP) and more than 19 mm Hg (highest quartile of PAOP). These curves were compared after log-log transformation with analysis of covariance. The association of 1/C PA and PVR with death was investigated with Cox proportional hazard models. The proportional hazards assumption was met in all cases. Adjusted Cox models were then performed forcing in Acute Physiology and Chronic Health Evaluation (APACHE) III score as a covariate. Receiver operator curves (ROCs) were constructed to compare the area under the curve for the association of PVR and 1/C PA with death and to determine the optimal cutpoint for both PVR and 1/C PA using the method of Youden. Survival analysis was then performed using methods of Kaplan-Meier for 1/C PA and PVR at the identified optimal cutpoint. Single linear regression was performed to determine associations of clinical variables with C PA and PVR. A two-tailed p value of less than 0.05 was considered statistically significant. All analyses were performed using StataSE version 14 (Stata Statistical Software; StataCorp LP, College Station, TX).
RESULTS
Demographic, clinical, and physiologic data are shown in Table 1 . Compared with survivors, those who died were older, were less likely to be Caucasian, had lower body surface area (BSA), were more likely to be on vasopressors, and had higher APACHE III scores. Those who died had worse hemodynamic profiles including lower systemic blood pressures, higher heart rate, and elevated markers of RV afterload ( Table 2) .
Demographic and clinical factors associated with C PA and PVR are summarized in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/C278). Clinical factors associated with both C PA and PVR included age, heart rate, BSA, and A-a gradient (p < 0.05 for all). Lower body temperature (β, −0.13; se, 0.06; p = 0.01) and higher ventilator driving pressure (β, 0.14; se, 0.01; p = 0.02) were associated with higher PVR, but neither factor was associated with C PA . Lower arterial pH (β, 0.11; se, 0.14; p = 0.04) was associated with lower C PA but not associated with PVR. Positive fluid balance (β, −0.13; se, 0.0009; p = 0.01) was associated with lower C PA but not associated with PVR.
As expected, PVR and C PA were related in an inverse hyperbolic manner (Fig. 1A) . Elevated left heart filling pressure Baseline for PVR, p = 0.006). After adjusting for APACHE III score, PVR remained a significant predictor of mortality (HR, 1.26; 95% CI, 1.05-1.5; p = 0.01), whereas only a trend remained for C PA (HR, 1.15; 95% CI, 0.99-1.34; p = 0.07). These findings were not mediated solely by CO nor SV-in univariate analyses, neither CO (HR, 0.91 per IQR increase; 95% CI, 0.70-1.18; p = 0.5) nor SV (HR, 0.78 per increase in IQR; 95% CI, 0.60-1.02; p = 0.07) was associated with mortality. The borderline association of mortality with SV attenuated when adjusting for APACHE score (HR, 0.88 per increase in IQR; 95% CI, 0.68-1.14; p = 0.3).
The area under the ROC curve for 1/C PA to predict 60-day death was 0.60 compared with 0.58 for PVR (p = 0.4). The optimal cutpoint to predict death for 1/C PA was 0.30 mm Hg/mL (3.33 mm Hg/mL for C PA ), which was 47% sensitive and 73% specific. The optimal cutpoint to predict death for PVR was 1.91 WU, which was 46% sensitive and 68% specific. Supplemental Digital Content 1, http://links.lww.com/CCM/ C278) although PVR did not (p = 0.2). In the PVR less than 3 WU cohort, subjects with lower C PA had lower SV and lower CI but similar PAOP (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/C278) than those with higher C PA . Figure 3 , A and B display the trends in mean PVR and C PA over the first four complete trial days (days 0, 1, 2, and 3) for subjects with available data. At trial enrollment, subjects who ultimately died had lower baseline C PA , and C PA did not change over the first four trial days (p = 0.9). Subjects who ultimately lived had higher baseline C PA and C PA increased over the first four trial days (p = 0.02), and an increasing C PA was therefore associated with a lower likelihood of death (HR, 0.58; 95% CI, 0.37-0.91; p = 0.02). Subjects who ultimately died had higher baseline PVR, which did not change over the first four trial days (p = 0.6). Consequently, the RC time increased in survivors (p = 0.02) yet remained unchanged in nonsurvivors, suggesting that survivors had less RV pulsatile load for a given PVR. Survivors also demonstrated the decreasing heart rate, increasing SV, and lower right atrial pressure, pulmonary artery pressure, and PAOP between day 0 and day 3 (Supplemental Table 3 
DISCUSSION
Major Findings
In this analysis of a modern ARDS cohort from FACTT, C PA -a marker of pulsatile RV afterload-and PVR-a marker of static RV afterload-are both modestly associated with 60-day all-cause mortality, and C PA remains predictive even when PVR is in the normal range. C PA and PVR are related in an inverse hyperbolic fashion, consistent with other disease states. The pulmonary vascular RC curve in ARDS is sensitive to left heart filling pressure, and elevated PAOP lowers compliance independent of resistance, which is anticipated and consistent with observations in other disease states. Finally, we demonstrate that C PA increases over time in patients who survive their ARDS while remaining constant in nonsurvivors.
RC Relationship in ARDS
We demonstrate for the first time in mechanically ventilated ARDS patients that C PA and PVR follow an inverse hyperbolic relationship. Pulmonary hypertension associated with respiratory failure was first described by Zapol and Snider (19) , and since then, the dependence of C PA on PVR has been suggested in a number of studies including those with normal subjects (20) , known or suspected pulmonary hypertension (8, 20, 21) , and interstitial lung disease (8) . This concept was perhaps best illustrated by Newman et al (22) who administered inhaled nitric oxide to subjects with vasoreactive pulmonary arterial hypertension (PAH), demonstrating with falling PVR, C PA increased in a predictable fashion, with little impact on the RC time. A consequence of this RC relationship is that in order to reduce pulsatile RV load, PVR must be lowered to the steep portion of the RC curve (e.g., 1-3 WU). Small changes in PVR could dramatically impact C PA , potentially making C PA a better discriminator of RV load and survival in this range of PVR.
C PA in ARDS Baseline C PA was associated with 60-day mortality in ARDS although it was not a clearly superior prognostic marker compared with PVR. PVR has been previously shown to predict mortality in the FACTT cohort by Bull et al (7) using different methodologies. The association of C PA with mortality attenuated when adjusted for APACHE score, whereas the association of PVR did not. Our finding that C PA was associated not only with fluid balance but also with acidosis, hypoxia, and tachycardia (variables included in APACHE) suggests that either C PA is more affected by variables associated with illness severity than PVR or that lower compliance itself impacts illness severity. Higher PAOP predictably decreased C PA at a given resistance. In this cohort, lower day 0 PAOP was associated with mortality. This "protective" association of higher PAOP could be a marker of more severe systemic vasodilatation, third spacing, and hence more severe hemodynamic compromise among those with low PAOP. This relationship contrasts with left heart failure where elevation in PAOP (and lower compliance) is pathogenic. This could explain why baseline C PA was not clearly superior to PVR in predicting mortality as factors other than RV load impacted outcome.
Compliance was predictive of mortality in subjects with PVR less than 3 WU, whereas PVR was not. Pellegrini (10) also found that C PA remained associated with mortality even when PVR was in the normal range in a cohort of left heart failure patients. Our results also follow from studies that have demonstrated the prognostic utility of estimated C PA in other disease states such as heart failure and primary pulmonary hypertension (9, 11, 12, 23) . There were no differences in baseline PAOP between survivors and nonsurvivors in the PVR less than 3 WU cohort despite differences in C PA . Because left heart pressures impacted baseline compliance less in our cohort, these findings may speak more to the impact of small changes in PVR on compliance and total RV load (i.e., steepness of the RC curve).
We also found that an increase in C PA during the study time course was associated with survival although PVR did not change dramatically in this group. The change in C PA was mediated at least in part by reduction in PAOP and less positive fluid balance. In a recent analysis from the FACTT dataset, it was noted that among patients with lower filling pressures at baseline, a fluid conservative strategy was associated with benefit (13) . Other studies in ARDS and critical illness have supported these findings as well (13, 24, 25) . Avoiding positive fluid balance, when possible, should result in higher C PAdyn and reduce pulsatile RV afterload.
Therapeutic Implications
Our findings represent associations of PVR and C PA with outcome, and it cannot be presumed that pulmonary vascular dysfunction causes increased mortality directly in this setting. Nonetheless, these associations should contribute to hypotheses regarding therapeutic implications of targeting pulmonary vascular dysfunction in ARDS. Although total RV load in the setting of a normal PVR likely remains modest, even when C PA is depressed, recent work has demonstrated that even borderline elevations in load may impact mortality (26) . Modifying RV load therapeutically in ARDS has not been well studied. Trials assessing inhaled nitric oxide (iNO) in ARDS have shown no improvement in outcome (27, 28) at a median dose across trials of 10 parts per million. However, there is heterogeneity in both the oxygenation response and the hemodynamic response to iNO in ARDS, both between patients and over time within the same patient (29) , and patients who respond to iNO have lower treatment-related PVR than nonresponders (30) . The impact of pulmonary vasodilators on right heart hemodynamics and the subsequent impact on outcome need additional study.
An "RV protective" approach to mechanical ventilation in ARDS has been proposed (31) (32) (33) (34) , which incorporates limiting plateau pressure, avoiding respiratory acidosis, and titrating ventilator variables to an endpoint of adequate RV function assessed with echocardiography. Although the clinical effect of this approach on RV afterload has not been demonstrated prospectively, our results confirm that these components of RV protection-including ventilator driving pressure and acidosis-are indeed associated with PVR and C PA and that fluid balance also plays an important role. Our results suggest that optimization of heart rate in patients with arrhythmia, avoidance of hypothermia (suggested by our study and others to increase PVR (35)), and avoiding positive fluid balance should be assessed in future studies of RV protection in ARDS. Our findings could contribute to the design of an RV protective approach to mechanical ventilation that should be evaluated prospectively. Although right heart catheterization use in ARDS is declining (36) , hemodynamics including C PA can be estimated by echocardiography (37) , and echo-estimated C PA is prognostic in PAH (11) . Longitudinal tracking of C PA with echocardiography is an attractive strategy in ARDS and should be investigated in prospective trials. Limitations This is a retrospective, observational study, and thus, our findings are hypothesis generating and represent associations only. As such, causality cannot be inferred from relationships reported in this study. For example, it is not possible to determine if the change in C PA promotes worsening hemodynamics, RV function, and survival or is simply a marker of illness severity. The specific cause of death was not available for this cohort, and therefore, it was not possible to determine if patients died of RV failure or other causes. Few patients in our cohort were treated with prone positioning, which has been demonstrated to have beneficial hemodynamic effects (38) This analysis is a hemodynamic analysis, whereas much of the literature defining the relationship between ARDS, outcome, and "cor pulmonale" relies on echocardiographic findings (5, 31, 33, 34) . Future studies should assess the echocardiographic correlates of C PA and PVR in ARDS, enabling noninvasive assessment in ARDS. An additional limitation is that SV/pulse pressure represents a lumped simplification for compliance, and some of this theory has recently been debated (39) . Other variables such as pulmonary artery elastance are also important lumped variables of RV afterload although they too have limitations, and how to best estimate pulmonary artery elastance remains controversial (40) . Hemodynamic measurements were made by study investigators at the bedside after formal hemodynamic assessment training. Although interpretation of hemodynamics may be variable among examiners even with training, we believe that this likely represents a best case scenario for clinical practice. Even with variability, the changes in compliance and association with outcome were statistically significant, and measurement error likely would bias toward the null. Finally, we necessarily restricted our analysis to only those FACTT subjects with a complete hemodynamic dataset at trial enrollment and prior to protocol mandated fluid management. Although it would be prudent to validate these findings in future cohorts, with declining use of the pulmonary artery catheter in ARDS, this will be challenging (36) .
In conclusion, we demonstrate an inverse hyperbolic relationship between C PA and PVR in a cohort of patients with ARDS, which is modified by left heart filling pressure. Baseline C PA and PVR both predict mortality, and C PA predicts mortality even when PVR is normal. Improvement in C PA over time is associated with survival. Patient factors including age and heart rate and disease-specific clinical factors such as fluid balance and ventilator driving pressure are associated with aspects of RV afterload. Future studies should assess the value of noninvasive assessment of C PA in ARDS and the impact of RV protective ARDS treatment on RV afterload and outcome.
